These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001716-31 A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction... 2007-05-25 due-trials
Reported results 2004-003116-33 A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin 2007-12-20 due-trials
Reported results 2005-000213-35 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reductio... 2017-07-11 due-trials
Not reported 2006-000168-10 A 4-week, double-masked, parallel-group, randomized , multicenter, proof of concept study comparing the efficacy and safety of two dose levels of BVT.28949 with placebo in patients with ocular hyperte... 2007-12-06 due-trials
Reported results 2006-003709-15 A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subj... 2011-11-22 due-trials
Not reported 2006-005967-25 A double-blind, placebo-controlled, randomized, parallel-group study evaluating the efficacy and tolerability of oral BVT.115959, a novel A2A agonist, versus placebo in the treatment of diabetic neuro... 2007-12-27 due-trials
Completed, but no date, and reported results 2007-002423-33 A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to infant formula versus placebo during one week of treatment in preterm infants born before week 32 of gestatio... bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002434-10 A prospective, randomised, double-blind crossover study comparing 0.15 g/L rhBSSL added to pasteurized breast milk versus placebo during one week of treatment in preterm infants born before week 32 of... 2010-02-16 bad-data
Reported results 2007-004063-21 An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. 2009-06-26 due-trials
Ongoing 2009-018146-38 Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interfe... not-yet-due
Trial is partly outside EEC, and reported results 2010-023909-35 A Prospective, Randomized, Double-Blind, Phase 3 Study Comparing rhBSSL and Placebo Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants Born Before Week 3... 2014-08-20 bad-data
Reported results 2012-002286-36 Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin. 2013-03-01 due-trials
Reported results 2013-004132-29 An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnosed ... 2015-12-04 due-trials
Trial is outside EEC, and reported results 2015-002526-39 A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects with Acute Leukemias Undergoing Myeloblative Therapy and Allogeneic Hematopoietic S... bad-data
Other 2017-000065-73 A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed with rFVIIIFc within a Timeframe of 60 Weeks in Severe Haemophilia A Patients with Inhibitors who have Failed P... not-yet-due
Exempt 2017-002806-10 An open, non-controlled, parallel, ascending multiple-dose, multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SOBI003 in pediatric MPS IIIA patients not-yet-due